A view from the Center

>

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

An integrated health ecosystem can be greater than the sum of its digital devices

by Felix Matthews, MD, MBA, managing director, and Christopher Zant, principal, Deloitte Consulting LLP

The real power of the internet of things (IoT) is the closed loop in which an array of smart devices gathers and shares meaningful data. This information is analyzed and interpreted, which ultimately leads to actionable interventions. In the digital world, the whole is often greater than the sum of its parts—this can be particularly true for an integrated digital health ecosystem.

Read more

Innovate or wait and see: Which path will health stakeholders follow?

by Joshua Lee, principal, and Bradley Allan Gallaher, senior manager, Deloitte Consulting LLP

In a recent blog post, our colleague Neal Batra drew parallels between the disruptive forces that altered the music industry 20 years ago and the outside organizations that are beginning to gain a foothold in health care. Health care certainly isn’t the first industry to undergo a major disruption, but it could be the most monumental.

Read more

‘Coop-etition’ could grow as medtech companies prepare for transformational innovation

by Glenn Snyder, Principal, MedTech Practice Leader, Deloitte Consulting LLP

I’ve been hearing the term “coop-etition” quite a bit recently as medical technology executives consider the impact outside organizations are beginning to have on their industry. There is an acknowledgement among many traditional device manufacturers that they might need to cooperate with consumer-centric/tech-savvy organizations as their world becomes more digital and increasingly consumer-focused.

Read more

STEP UP: When paired with gamification and a science-based engagement program, wearables can boost (and sustain) activity levels

by Greg Szwartz, Life Sciences data science practice lead, Deloitte Consulting LLP

At the Temple Mount in Jerusalem, the ancient construction is strikingly precise. Every stone in the outer wall appears to have been meticulously placed, and all of the stairs are exactly the same size and shape. The last flight of stairs leading to the entrance, however, is noticeably different. The width and height of the of the steps are erratic—some are narrow while others are broad.

Read more

Why improving inclusion and diversity in clinical trials should be a research priority

by Karen Taylor, Research Director, UK Centre for Health Solutions, Deloitte Services LP

Several weeks ago, I participated in a panel discussion on inclusion and diversity in clinical trials. My research for the event and the discussion that ensued led me to conclude that while there have been some improvements, the pharma industry continues to struggle to recruit enough trial participants from important demographic groups, especially women, racial and ethnic minorities,

Read more

Star Trek medicine in the age of a Flintstones reimbursement system: Can value-based contracting pull all stakeholders into the same era?

by Jeff Morgan, Managing Director, Deloitte Consulting LLP

“Star Trek medicine in the age of a Flintstones reimbursement system,” was a quote I heard during this year’s JP Morgan Healthcare conference back in January…and it has stuck with me. The comment drove home the point that our health care reimbursement system needs to evolve to keep pace with the innovation that we are seeing in drug development.

Read more